trial · primary record
Maridebart Cafraglutide
Atherosclerotic Cardiovascular Disease
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 12800 |
| Primary completion | 2030-09-29 |
| Primary endpoint | Time to First Occurrence of a Composite Endpoint Consisting of: CV Death, Myocardial Infarction (MI), or Ischemic Stroke (3-point Major Adverse Cardiac Events [3-P MACE]) |
| Registry ID | NCT07037433 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:31:55.974Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07037433
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Maridebart Cafraglutide · compound